[go: up one dir, main page]

AR038563A1 - Composicion de ziprasidona y controles sinteticos - Google Patents

Composicion de ziprasidona y controles sinteticos

Info

Publication number
AR038563A1
AR038563A1 ARP030100527A ARP030100527A AR038563A1 AR 038563 A1 AR038563 A1 AR 038563A1 AR P030100527 A ARP030100527 A AR P030100527A AR P030100527 A ARP030100527 A AR P030100527A AR 038563 A1 AR038563 A1 AR 038563A1
Authority
AR
Argentina
Prior art keywords
ziprasidone
ziprasidone composition
synthetic controls
composition
synthetic
Prior art date
Application number
ARP030100527A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27761437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR038563(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR038563A1 publication Critical patent/AR038563A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Indole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Composición de ziprasidona que comprende no más que aproximadamente 1000 ppm de ziprasidona desclorada, preferiblemente no más que aproximadamente 500 ppm de ziprasidona desclorada, y más preferiblemente no más que aproximadamente 100 ppm de ziprasidona desclorada. Se proporcionan también procedimientos para sintetizar y utilizar dichas composiciones de ziprasidona.
ARP030100527A 2002-02-20 2003-02-18 Composicion de ziprasidona y controles sinteticos AR038563A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35880602P 2002-02-20 2002-02-20
US35903802P 2002-02-21 2002-02-21
US36045902P 2002-02-27 2002-02-27

Publications (1)

Publication Number Publication Date
AR038563A1 true AR038563A1 (es) 2005-01-19

Family

ID=27761437

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100527A AR038563A1 (es) 2002-02-20 2003-02-18 Composicion de ziprasidona y controles sinteticos

Country Status (41)

Country Link
EP (1) EP1476162B1 (es)
JP (1) JP4554938B2 (es)
KR (1) KR100773622B1 (es)
CN (2) CN1635892A (es)
AP (1) AP2004003103A0 (es)
AR (1) AR038563A1 (es)
AT (1) ATE359787T1 (es)
AU (2) AU2003206035A1 (es)
BR (1) BR0307833A (es)
CA (1) CA2475302C (es)
CO (1) CO5611138A2 (es)
CY (1) CY1106467T1 (es)
DE (1) DE60313289T2 (es)
DK (1) DK1476162T3 (es)
EA (1) EA007866B1 (es)
EC (1) ECSP045239A (es)
ES (1) ES2283745T3 (es)
GE (1) GEP20074030B (es)
GT (1) GT200300040A (es)
HR (1) HRP20040711A2 (es)
IL (1) IL163277A (es)
IS (1) IS7344A (es)
MA (1) MA27177A1 (es)
MX (1) MXPA04006993A (es)
MY (1) MY139523A (es)
NO (2) NO20043902L (es)
NZ (1) NZ534443A (es)
OA (1) OA12774A (es)
PA (1) PA8567001A1 (es)
PE (1) PE20030942A1 (es)
PL (1) PL372238A1 (es)
PT (1) PT1476162E (es)
RS (1) RS60404A (es)
SI (1) SI1476162T1 (es)
SV (1) SV2004001485A (es)
TN (1) TNSN04159A1 (es)
TW (1) TW200307546A (es)
UA (1) UA77057C2 (es)
UY (1) UY27668A1 (es)
WO (1) WO2003070246A1 (es)
ZA (1) ZA200406276B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520240A (en) 2000-03-06 2005-04-29 Acadia Pharm Inc Azacyclic compounds for use in the treatment of serotonin related diseases
ATE466014T1 (de) 2001-12-28 2010-05-15 Acadia Pharm Inc Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
BR0312217A (pt) 2002-06-24 2005-05-10 Acadia Pharm Inc Compostos, métodos de inibição da atividade/ativação de um receptor monoaminérgico e método de tratamento de condição doentia associada a um receptor de monoaminergético
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
AU2003300814A1 (en) 2002-12-04 2004-06-23 Dr. Reddy's Laboratories Inc. Polymorphic forms of ziprasidone and its hydrochloride
WO2004064738A2 (en) 2003-01-16 2004-08-05 Acadia Pharmaceuticals Inc. Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
DE602004013405T2 (de) 2003-03-17 2009-05-07 Teva Pharmaceutical Industries Ltd. Polymorphe formen von valsartan
WO2004094392A1 (en) * 2003-04-21 2004-11-04 Teva Pharmaceutical Industries Ltd. Process for the preparation of valsartan
WO2005016325A2 (en) 2003-06-03 2005-02-24 Teva Pharmaceutical Industries Ltd. CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
WO2005040160A2 (en) 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
WO2005061493A2 (en) * 2003-12-18 2005-07-07 Teva Pharmaceutical Industries Ltd. Polymorphic form b2 of ziprasidone base
ATE451367T1 (de) 2004-02-27 2009-12-15 Ranbaxy Lab Ltd Verfahren zur herstellung von ziprasidon
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
PL2289879T3 (pl) 2004-09-27 2015-05-29 Acadia Pharm Inc Synteza formy krystalicznej soli winianowej n-(4-fluorobenzylo)-n-(1-metylopiperydyn-4-ylo)-n'-(4-(2-metylopropyloksy)fenylometylo)karbamidu
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
ES2250000B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Procedimiento para la preparacion de ziprasidona.
EP1841764A1 (en) * 2005-01-27 2007-10-10 Hetero Drugs Limited Process for ziprasidone using novel intermediates
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
CN100491375C (zh) * 2006-07-01 2009-05-27 浙江美诺华药物化学有限公司 一种齐拉西酮的制备方法
ES2423485T3 (es) 2007-03-19 2013-09-20 Acadia Pharmaceuticals Inc. Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos
CN102234272A (zh) * 2010-04-21 2011-11-09 上海医药工业研究院 盐酸齐拉西酮半水合物的制备方法
CN102234273B (zh) * 2010-04-21 2015-08-05 上海医药工业研究院 甲磺酸齐拉西酮半水合物及其制备方法
SI3325444T1 (sl) 2015-07-20 2021-11-30 Acadia Pharmaceuticals Inc. Postopki za pripravo N-(4-fluorobenzil)-N-(1-metilpiperidin-4-il)-N'- (4-(2-metilpropiloksi)fenilmetil)karbamida in njegove tartratne soli in polimorfne oblike C
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
EP3558311A1 (en) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
CN108239085A (zh) * 2016-12-26 2018-07-03 四川科瑞德凯华制药有限公司 一种甲磺酸齐拉西酮的纯化及制备方法
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
EP3675827A1 (en) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
CN112724066B (zh) * 2021-02-04 2022-10-21 海南鑫开源医药科技有限公司 一种盐酸齐拉西酮中间体中的二卤杂质及其制备方法
CN116046966A (zh) * 2023-01-17 2023-05-02 北京协和建昊医药技术开发有限责任公司 一种流动相配置装置及其配置方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
DE69611253T2 (de) 1995-11-07 2001-04-05 Pfizer Inc., New York Verfahren und zwischenprodukte für die herstellung von 3-(1-piperazinyl)-1,2-benzisothiazolen
JP3102896B2 (ja) * 1996-05-07 2000-10-23 ファイザー インク． ５―（２―（４―（１，２―ベンズイソチアゾール―３―イル）―１―ピペラジニル）エチル）―６―クロロ―１，３―ジヒドロ―２（１ｈ）―インドール―２―オン（＝ジプラシドン）のメシレート三水和物、その調製法およびドーパミンｄ２アンタゴニストとしてのその使用
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations

Also Published As

Publication number Publication date
NO20100584L (no) 2004-09-17
EA200400815A1 (ru) 2004-12-30
ATE359787T1 (de) 2007-05-15
DE60313289T2 (de) 2007-12-27
DK1476162T3 (da) 2007-07-02
CN1635892A (zh) 2005-07-06
MXPA04006993A (es) 2004-11-10
NO20043902L (no) 2004-09-17
UY27668A1 (es) 2003-10-31
WO2003070246A1 (en) 2003-08-28
AU2003206035A1 (en) 2003-09-09
GEP20074030B (en) 2007-02-12
RS60404A (sr) 2006-10-27
AU2009202008A1 (en) 2009-06-11
PL372238A1 (en) 2005-07-11
EP1476162B1 (en) 2007-04-18
PA8567001A1 (es) 2003-12-10
ECSP045239A (es) 2004-09-28
SV2004001485A (es) 2004-05-07
ZA200406276B (en) 2005-09-20
IS7344A (is) 2004-07-05
PT1476162E (pt) 2007-06-25
UA77057C2 (en) 2006-10-16
CY1106467T1 (el) 2012-01-25
HRP20040711A2 (en) 2004-12-31
GT200300040A (es) 2007-01-12
EA007866B1 (ru) 2007-02-27
KR20040086417A (ko) 2004-10-08
TW200307546A (en) 2003-12-16
PE20030942A1 (es) 2003-11-08
DE60313289D1 (de) 2007-05-31
JP2005525347A (ja) 2005-08-25
CA2475302A1 (en) 2003-08-28
MA27177A1 (fr) 2005-01-03
CA2475302C (en) 2009-05-12
ES2283745T3 (es) 2007-11-01
CO5611138A2 (es) 2006-02-28
BR0307833A (pt) 2004-12-07
TNSN04159A1 (fr) 2007-03-12
OA12774A (en) 2006-07-04
KR100773622B1 (ko) 2007-11-05
AP2004003103A0 (en) 2004-09-30
CN101735212A (zh) 2010-06-16
MY139523A (en) 2009-10-30
JP4554938B2 (ja) 2010-09-29
NZ534443A (en) 2007-07-27
SI1476162T1 (sl) 2007-08-31
EP1476162A1 (en) 2004-11-17
IL163277A (en) 2010-05-31

Similar Documents

Publication Publication Date Title
AR038563A1 (es) Composicion de ziprasidona y controles sinteticos
AU2002213336A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
DE60236600D1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
CR8291A (es) Formas polimorficas 3-(4-amino-1-oxo-1,3 dihidro -isoindol-2-il)-piperidin-2, 6-diona
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
DK1560812T3 (da) Aminocyclohexyletherforbindelser og anvendelser deraf
DE60019586D1 (de) Myostatin genpromoter und inhibierung dessen aktivierung
MXPA06003363A (es) Derivados de fenil-piperazina como moduladores de receptores muscarinicos.
NO20050664L (no) 2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer
MXPA06000888A (es) Composicion, toalla limpiadora y metodo para limpiar, proteger e impartir brillo a un substrato.
MXPA04003755A (es) Endoprotesis vasculares.
DE50310579D1 (de) Furancarboxamide
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
BG105710A (en) 5ht1 antagonists for antidepressant therapy
BRPI0408117A (pt) compostos heterocìclicos bifuncionais e métodos de produção e uso dos mesmos
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
MXPA06003345A (es) Derivados de aminopiridina como inhibidores de la no-sintasa inducible.
DE50311756D1 (de) Mikrobizide oxathiincarboxamide
TW200716130A (en) Purified form of tanaproget
ATE394105T1 (de) Substituierte 4,5-dihydro-1,2,4-triazin-3-one, 1, 2,4-triazin-3-one sowie deren verwendung als fungizide und insektizide
YU26001A (sh) Derivati ureidopiperidina kao selektivni antagonisti ljudskih nk3 receptora
ID27656A (id) Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
PA8478901A1 (es) Isoquinolinas
CU23343A3 (es) Composición de ziprasidona y controles sintéticos
CR7418A (es) Composicion de ziprasidona y controles sinteticos

Legal Events

Date Code Title Description
FB Suspension of granting procedure